MX386070B - Metodo de tratamiento basado en combinacion. - Google Patents
Metodo de tratamiento basado en combinacion.Info
- Publication number
- MX386070B MX386070B MX2016009167A MX2016009167A MX386070B MX 386070 B MX386070 B MX 386070B MX 2016009167 A MX2016009167 A MX 2016009167A MX 2016009167 A MX2016009167 A MX 2016009167A MX 386070 B MX386070 B MX 386070B
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- treatment method
- based treatment
- administering
- patient
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000003915 DNA Topoisomerases Human genes 0.000 abstract 1
- 108090000323 DNA Topoisomerases Proteins 0.000 abstract 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461927376P | 2014-01-14 | 2014-01-14 | |
| US201462080775P | 2014-11-17 | 2014-11-17 | |
| PCT/US2015/011239 WO2015108876A1 (en) | 2014-01-14 | 2015-01-13 | Combination-based treatment method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016009167A MX2016009167A (es) | 2016-09-09 |
| MX386070B true MX386070B (es) | 2025-03-18 |
Family
ID=52469293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016009167A MX386070B (es) | 2014-01-14 | 2015-01-13 | Metodo de tratamiento basado en combinacion. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10653689B2 (OSRAM) |
| EP (1) | EP3094331B1 (OSRAM) |
| JP (1) | JP6758195B2 (OSRAM) |
| KR (1) | KR102501566B1 (OSRAM) |
| AU (1) | AU2015206667B2 (OSRAM) |
| CA (1) | CA2934552C (OSRAM) |
| MX (1) | MX386070B (OSRAM) |
| WO (1) | WO2015108876A1 (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102611382B1 (ko) | 2018-09-19 | 2023-12-07 | 삼성디스플레이 주식회사 | 터치 감지 유닛과 그를 포함하는 표시 장치 |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120073370A (ko) * | 2003-09-17 | 2012-07-04 | 넥타르 테라퓨틱스 | 다분지형 고분자 전구약물 |
| KR20090130156A (ko) * | 2004-09-22 | 2009-12-17 | 화이자 인코포레이티드 | 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는 치료 배합물 |
| JP2006124351A (ja) | 2004-11-01 | 2006-05-18 | Yakult Honsha Co Ltd | 徐放性抗腫瘍剤組成物 |
| DK2338487T3 (da) | 2006-01-17 | 2013-12-09 | Abbvie Bahamas Ltd | Kombinationsterapi med PARP-inhibitorer |
| WO2007092646A2 (en) | 2006-02-09 | 2007-08-16 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| EP2038654A4 (en) * | 2006-06-12 | 2010-08-11 | Bipar Sciences Inc | METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS |
| AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| US20090149397A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| CA3063465C (en) | 2009-11-18 | 2023-01-03 | Nektar Therapeutics | Acid salt forms of polymer-drug conjugates and alkoxylation methods |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
-
2015
- 2015-01-13 CA CA2934552A patent/CA2934552C/en active Active
- 2015-01-13 EP EP15704116.1A patent/EP3094331B1/en not_active Revoked
- 2015-01-13 JP JP2016563904A patent/JP6758195B2/ja active Active
- 2015-01-13 WO PCT/US2015/011239 patent/WO2015108876A1/en not_active Ceased
- 2015-01-13 MX MX2016009167A patent/MX386070B/es unknown
- 2015-01-13 KR KR1020167020229A patent/KR102501566B1/ko active Active
- 2015-01-13 AU AU2015206667A patent/AU2015206667B2/en active Active
- 2015-01-13 US US15/111,065 patent/US10653689B2/en active Active
-
2020
- 2020-04-15 US US16/849,781 patent/US20200237747A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP6758195B2 (ja) | 2020-09-23 |
| WO2015108876A1 (en) | 2015-07-23 |
| EP3094331B1 (en) | 2017-12-27 |
| EP3094331A1 (en) | 2016-11-23 |
| KR102501566B1 (ko) | 2023-02-17 |
| KR20160106086A (ko) | 2016-09-09 |
| US20200237747A1 (en) | 2020-07-30 |
| JP2017502091A (ja) | 2017-01-19 |
| CA2934552A1 (en) | 2015-07-23 |
| AU2015206667B2 (en) | 2020-05-14 |
| CA2934552C (en) | 2021-03-30 |
| AU2015206667A1 (en) | 2016-07-07 |
| US20160339013A1 (en) | 2016-11-24 |
| MX2016009167A (es) | 2016-09-09 |
| US10653689B2 (en) | 2020-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284173A (en) | Methods of conditioning patients for t cell therapy | |
| ECSP17029371A (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| ECSP17015977A (es) | Terapia de combinacion | |
| MX373103B (es) | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). | |
| UY34698A (es) | Combinaciones farmacéuticas que comprenden un análogo de tionucleótidos | |
| LT3137169T (lt) | Lizinui specifinės demetilazės-1 inhibitoriai | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| DK3230736T3 (da) | Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter | |
| BR112016030697A2 (pt) | inibidores da desmetilase-1 específica da lisina | |
| MX2017005457A (es) | Metodos y compuestos agonistas de gip. | |
| LT3164380T (lt) | Lizinui specifiniai demetilazės-1 inhibitoriai | |
| BR112017000042A2 (pt) | inibidores de desmetilase-1 lisina-específica | |
| PL4023222T3 (pl) | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q | |
| IL256246A (en) | Targeted conjugates to ksp inhibitors | |
| DK3131497T3 (da) | Instrumenter til anvendelse med implanterbare indkapslingsindretninger | |
| TWD172924S (zh) | 跳躍運動裝置 | |
| EA201790312A1 (ru) | Комбинации лекарственных средств для лечения множественной миеломы | |
| MX2018007390A (es) | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| CR20160448A (es) | Nuevos derivados de piridina | |
| EA201692534A1 (ru) | Способы лечения гипотонии | |
| EP3756626C0 (en) | ASTRAGALOCALCANEAN JOINT IMPLANT | |
| MA54761A (fr) | Administration d'un inhibiteur de signalisation de trans-signalisation par il-6 sélectif | |
| BR112015024771A2 (pt) | cateter | |
| CL2016000396A1 (es) | Tratamiento contra el mieloma múltiple | |
| MX386070B (es) | Metodo de tratamiento basado en combinacion. |